ORIGINAL RESEARCH article
Front. Oncol.
Sec. Radiation Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1623313
This article is part of the Research TopicInnovative Approaches in Precision Radiation OncologyView all 14 articles
Analysis of Imaging Signatures in 18 F-DOPA PET of Glioblastoma Treated with Dose-Escalated Radiotherapy
Provisionally accepted- 1Department of Radiation Oncology, Mayo Clinic, Rochester, United States
- 2Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, United States
- 3Department of Radiology, Mayo Clinic, Rochester, United States
- 4Department of Medical Oncology, Mayo Clinic, Rochester, United States
- 5Department of Neurology, Mayo Clinic, Rochester, United States
- 6Mayo Clinic, Department of Neurology, Rochester, MN, United States
- 7University of Maryland, Department of Radiation Oncology, Baltimore, MD, United States
- 8University of California San Francisco Medical Center, San Francisco, CA, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background/Objectives: 18 F-DOPA is an amino acid radiotracer with high uptake in glioblastoma and low uptake in normal brain. Patients underwent pre-radiation and post-radiation 18 F-DOPA PET scans on a prospective clinical trial. This analysis investigates quantitative image features correlated with prognosis and treatment response to identify patients who benefit the most from dose-escalated therapy. Methods: Quantitative image features from 18 F-DOPA PET scans of 58 glioblastoma patients were extracted from the high uptake region (TBR>2.0) in both pre-RT and early post-RT follow-up PET images, which were then refined using Pearson pair correlation. To explore the possibility to identify patients who benefit the most from dose-escalated therapy, pre-irradiation features were identified with univariate Cox regression analysis. Classifications with simple threshold or with Decision Tree models were carried out to categorize patients into distinct survival groups. Additionally, the features with notable changes before and after RT were identified and the temporal patterns of these changes between the survival groups were compared. Multivariates cox analysis was performed to assess the prognostic value of delta features in survival analysis; Results: The pre-irradiation features demonstrated predictive capability in distinguishing survival groups, yielding an accuracy of 0.78 on the reserved test dataset. We also pinpointed eight quantitative features that exhibited a significant difference before and after radiotherapy in patients with MGMT-unmethylated glioblastoma. The change of the features presented different patterns between the survival groups separated by median overall survival and the inclusion of delta features can enhance the accuracy of survival analysis. Conversely, for patients with methylated MGMT, no feature displayed such significant changes between preRT and early postRT. Conclusions: Our study showcased the potential of employing quantitative features derived from 18 F-DOPA images to refine the stratification of patients with unmethylated MGMT for dose escalated therapy. Moreover, the change of these features can serve as valuable tools for monitoring treatment responses following radiotherapy.
Keywords: Glioblastoma, Radiotherapy, 18 F-DOPA PET, treatment response, quantitative imaging
Received: 05 May 2025; Accepted: 25 Jul 2025.
Copyright: © 2025 Qian, Pafundi, Breen, Brown, Hunt, Jacobson, Johnson, Kaufmann, Kemp, Kizilbash, Lowe, Ruff, Sarkaria, Uhm, Zakhary, Seaberg, Wan Chan Tseung, Yan, Zhang, Laack and Brinkmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jing Qian, Department of Radiation Oncology, Mayo Clinic, Rochester, United States
Debra H Brinkmann, Department of Radiation Oncology, Mayo Clinic, Rochester, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.